Literature DB >> 17533050

Contribution of STAT3 to the activation of survivin by GM-CSF in CD34+ cell lines.

Lubing Gu1, Kuang-Yueh Chiang, Ningxi Zhu, Harry W Findley, Muxiang Zhou.   

Abstract

OBJECTIVE: Granulocyte macrophage colony-stimulating factor (GM-CSF) has been shown to specifically stimulate proliferation of CD34(+) hematopoietic progenitor cells. Although signal transducers and activators of transcription 3 (STAT3) is believed essential for transduction of GM-CSF-induced cell proliferation, the signaling mediated by STAT3 is not completely understood. Because survivin regulates cell proliferation and survival via its antiapoptotic function, we studied the link between STAT3 signaling and survivin expression in CD34(+) cells.
METHODS: GM-CSF-induced STAT3 and survivin expression in CD34(+) cells was examined by Western blot assay. GM-CSF-activated survivin promoter activity was analyzed by gene transfection and reporter assays. The binding of STAT3 to the survivin promoter was evaluated by chromatin immunoprecipitation and electrophoretic mobility shift assay. Western blotting and flow cytometry were utilized to test the effect of Janus family of tyrosine kinases (JAK) inhibitor and STAT3 small interfering RNA (siRNA) on cell apoptosis.
RESULTS: We found that GM-CSF stimulates survivin promoter activity in CD34(+) KG-1 cells, and STAT3 binds to the core survivin promoter containing a STAT response element TT(N)(5)AA at sites -264 to -256. Mutation or deletion of this STAT response element completely abolished the effects of GM-CSF on survivin promoter activity. Furthermore, addition of either JAK inhibitor or STAT3 siRNA was able to inhibit GM-CSF-induced survivin promoter activity and survivin expression. Inhibition of survivin by STAT3 siRNA or by withdrawal of GM-CSF in a GM-CSF-dependent, CD34(+) line TF-1 decreased cell growth and increased apoptosis.
CONCLUSION: Altogether, our results suggest that survivin is a transcriptional target of STAT3, and that GM-CSF-stimulated CD34(+) cell proliferation is regulated by the JAK/STAT3/survivin signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17533050     DOI: 10.1016/j.exphem.2007.03.007

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  16 in total

Review 1.  Transcriptional regulation of the survivin gene.

Authors:  Romain Boidot; Frédérique Végran; Sarab Lizard-Nacol
Journal:  Mol Biol Rep       Date:  2013-11-07       Impact factor: 2.316

2.  BCR-ABL induces tyrosine phosphorylation of YAP leading to expression of Survivin and Cyclin D1 in chronic myeloid leukemia cells.

Authors:  Kenta Moriyama; Toshiyuki Hori
Journal:  Int J Hematol       Date:  2019-08-19       Impact factor: 2.490

3.  Signal transducer and activator of transcription 3 (STAT3) and survivin induction by varicella-zoster virus promote replication and skin pathogenesis.

Authors:  Nandini Sen; Xibing Che; Jaya Rajamani; Leigh Zerboni; Phillip Sung; Jason Ptacek; Ann M Arvin
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-21       Impact factor: 11.205

4.  GM-CSF: a role in immune and inflammatory reactions in the intestine.

Authors:  Laia Egea; Yoshihiro Hirata; Martin F Kagnoff
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2010-12       Impact factor: 3.869

5.  Expression profile and specific network features of the apoptotic machinery explain relapse of acute myeloid leukemia after chemotherapy.

Authors:  Marco Ragusa; Giuseppe Avola; Rosario Angelica; Davide Barbagallo; Maria Rosa Guglielmino; Laura R Duro; Alessandra Majorana; Luisa Statello; Loredana Salito; Carla Consoli; Maria Grazia Camuglia; Cinzia Di Pietro; Giuseppe Milone; Michele Purrello
Journal:  BMC Cancer       Date:  2010-07-19       Impact factor: 4.430

6.  Deletion of caveolin-1 protects hyperoxia-induced apoptosis via survivin-mediated pathways.

Authors:  Meng Zhang; Ling Lin; Seon-Jin Lee; Li Mo; Jiaofei Cao; Emeka Ifedigbo; Yang Jin
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2009-09-18       Impact factor: 5.464

Review 7.  Therapy with JAK2 inhibitors for myeloproliferative neoplasms.

Authors:  Fabio P S Santos; Srdan Verstovsek
Journal:  Hematol Oncol Clin North Am       Date:  2012-08-21       Impact factor: 3.722

Review 8.  New wirings in the survivin networks.

Authors:  D C Altieri
Journal:  Oncogene       Date:  2008-10-20       Impact factor: 9.867

9.  Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).

Authors:  Kuo-Pao Lai; Chiung-Kuei Huang; Lei-Ya Fang; Kouji Izumi; Chi-Wen Lo; Ronald Wood; Jon Kindblom; Shuyuan Yeh; Chawnshang Chang
Journal:  Mol Endocrinol       Date:  2013-07-26

Review 10.  Pancreatic cancer chemoprevention by phytochemicals.

Authors:  Srinivas Reddy Boreddy; Sanjay K Srivastava
Journal:  Cancer Lett       Date:  2012-10-27       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.